Upcoming event
18th European Multidisciplinary Congress on Urological Cancers
Back

Tag: pembrolizumab

First-line pembrolizumab + lenvatinib + belzutifan or MK-1308A + lenvatinib in advanced RCC: Randomized open-label phase 3 LITESPARK-012 study

Perioperative pembrolizumab plus metastasis-directed therapy versus MDT alone in patients with oligometastatic renal cell carcinoma: The randomized phase II PE-PE trial